These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 19124371

  • 1. Adverse events associated with intranasal influenza vaccine in the United States.
    Vasu N, Ghaffari G, Craig ET, Craig TJ.
    Ther Adv Respir Dis; 2008 Aug; 2(4):193-8. PubMed ID: 19124371
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 3. Live attenuated influenza vaccine in children.
    Ambrose CS, Walker RE, Connor EM.
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):206-12. PubMed ID: 17055372
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.
    Belshe RB, Ambrose CS, Yi T.
    Vaccine; 2008 Sep 12; 26 Suppl 4():D10-6. PubMed ID: 18611422
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD, D153-P504 LAIV Study Group.
    Pediatr Infect Dis J; 2009 May 12; 28(5):365-71. PubMed ID: 19395948
    [Abstract] [Full Text] [Related]

  • 11. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.
    Tennis P, Toback SL, Andrews EB, McQuay LJ, Ambrose CS.
    Vaccine; 2012 Sep 14; 30(42):6099-102. PubMed ID: 22841479
    [Abstract] [Full Text] [Related]

  • 12. A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years.
    Tennis P, Toback SL, Andrews E, McQuay LJ, Ambrose CS.
    Vaccine; 2011 Jul 12; 29(31):4947-52. PubMed ID: 21596087
    [Abstract] [Full Text] [Related]

  • 13. Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine.
    Gagnon R, Primeau MN, Des Roches A, Lemire C, Kagan R, Carr S, Ouakki M, Benoît M, De Serres G, PHAC-CIHR Influenza Research Network.
    J Allergy Clin Immunol; 2010 Aug 12; 126(2):317-23. PubMed ID: 20579720
    [Abstract] [Full Text] [Related]

  • 14. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.
    Pediatrics; 2007 Sep 12; 120(3):e553-64. PubMed ID: 17698577
    [Abstract] [Full Text] [Related]

  • 15. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.
    Baxter R, Toback SL, Sifakis F, Hansen J, Bartlett J, Aukes L, Lewis N, Wu X, Ambrose CS.
    Vaccine; 2012 Apr 19; 30(19):2989-98. PubMed ID: 22386746
    [Abstract] [Full Text] [Related]

  • 16. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies.
    Ambrose CS, Wu X, Knuf M, Wutzler P.
    Vaccine; 2012 Jan 20; 30(5):886-92. PubMed ID: 22155144
    [Abstract] [Full Text] [Related]

  • 17. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age.
    Baxter R, Toback SL, Sifakis F, Hansen J, Bartlett J, Aukes L, Lewis N, Wu X, Ambrose CS.
    Vaccine; 2012 Apr 26; 30(20):3053-60. PubMed ID: 22425787
    [Abstract] [Full Text] [Related]

  • 18. Safety of live attenuated influenza vaccine in atopic children with egg allergy.
    Turner PJ, Southern J, Andrews NJ, Miller E, Erlewyn-Lajeunesse M, SNIFFLE Study Investigators.
    J Allergy Clin Immunol; 2015 Aug 26; 136(2):376-81. PubMed ID: 25684279
    [Abstract] [Full Text] [Related]

  • 19. Benefits and risks of live attenuated influenza vaccine in young children.
    Oster G, Weycker D, Edelsberg J, Nichol KL, Klein JO, Belshe RB.
    Am J Manag Care; 2010 Sep 26; 16(9):e235-44. PubMed ID: 21250400
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
    Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J.
    Vaccine; 2009 Feb 11; 27(7):1101-10. PubMed ID: 19095024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.